Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Phase 3

Completed

Conditions: Crohn Disease

Interventions: Drug: BI 695501
Drug: HUMIRA

First Posted Date: 2016-08-18

Last Posted Date: 2020-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 147

Registration Number: NCT02871635

Locations: 🇺🇸
MGG Group Co. Inc. / Chevy Chase Clinical Research,, Chevy Chase, Maryland, United States
🇺🇸
Borland-Groover Clinic, Jacksonville, Florida, United States
🇺🇸
Advance Medical Research Center, Miami, Florida, United States

and more 89 locations

Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Vahelva® Respimat® (Tiotropium + Olodaterol fixed dose combination)

First Posted Date: 2016-08-12

Last Posted Date: 2022-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3223

Registration Number: NCT02864407

Locations: 🇰🇷
Chonnam National University Hospital, One Or Multiple Sites, Korea, Republic of

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: DPP-4 inhibitors

First Posted Date: 2016-08-12

Last Posted Date: 2024-11-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 333580

Registration Number: NCT02864914

Locations: 🇬🇧
RTI health solutions, One Or Multiple Sites, United Kingdom

Transporter Cocktail Mutual Interaction

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Furosemide
Drug: Metformin
Drug: Digoxin
Drug: Metformin hydrochloride
Drug: Rosuvastatin

First Posted Date: 2016-08-03

Last Posted Date: 2023-11-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02854527

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 655130 (spesolimab)
Drug: Placebo

First Posted Date: 2016-08-02

Last Posted Date: 2024-03-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02852824

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Fluvoxamine
Drug: BI 409306 - Powder for oral solution (PfOS)
Drug: BI 409306 - film coated tablet

First Posted Date: 2016-08-02

Last Posted Date: 2024-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02853136

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium
Drug: Olodaterol

First Posted Date: 2016-08-02

Last Posted Date: 2019-09-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 106

Registration Number: NCT02853123

Locations: 🇧🇪
Hasselt - PRAC Aumann, J-L, Hasselt, Belgium
🇨🇦
McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇨🇦
McMaster Univ. Medical Centre, Hamilton, Ontario, Canada

and more 10 locations

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Humira
Drug: BI 695501

First Posted Date: 2016-08-01

Last Posted Date: 2019-02-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 318

Registration Number: NCT02850965

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Alliance Dermatology and MOHS Center PC, Phoenix, Arizona, United States
🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States

and more 51 locations

Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiolto

First Posted Date: 2016-08-01

Last Posted Date: 2019-12-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1335

Registration Number: NCT02850978

Patient Convenience Study- NIS RELATE

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Pradaxa (dabigatran)
Drug: Vitamin K antagonist

First Posted Date: 2016-07-29

Last Posted Date: 2019-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1313

Registration Number: NCT02849509

Locations: 🇰🇷
Pusan National Univ. Hosp, Busan, Korea, Republic of
🇰🇷
Sejong General Hospital, Bucheon, Korea, Republic of
🇮🇩
Harapan Kita National Cardiovascular Center, Jakarta Barat, Indonesia

and more 47 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy